828243-30-7 Usage
General Description
3-(1-(tert-butoxycarbonyl)piperidin-4-yl)benzoic acid is a chemical compound with the molecular formula C20H25NO4. It is a piperidine derivative with a tert-butoxycarbonyl (Boc) protecting group attached to the piperidine nitrogen atom and a benzoic acid group attached to the piperidine ring. The compound is often used in organic synthesis and medicinal chemistry as a building block for the synthesis of various pharmaceuticals and biologically active molecules. Its unique structure and functional groups make it a versatile intermediate in the preparation of diverse chemical compounds. The tert-butoxycarbonyl protecting group is commonly used to temporarily protect amine groups in organic synthesis, allowing for selective functionalization of other parts of the molecule. Overall, 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)benzoic acid is an important compound with applications in both chemical research and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 828243-30-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,2,8,2,4 and 3 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 828243-30:
(8*8)+(7*2)+(6*8)+(5*2)+(4*4)+(3*3)+(2*3)+(1*0)=167
167 % 10 = 7
So 828243-30-7 is a valid CAS Registry Number.
828243-30-7Relevant articles and documents
Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities
Tang, Haifeng,Yan, Yan,Feng, Zhe,De Jesus, Reynalda K.,Yang, Lihu,Levorse, Dorothy A.,Owens, Karen A.,Akiyama, Taro E.,Bergeron, Raynald,Castriota, Gino A.,Doebber, Thomas W.,Ellsworth, Kenneth P.,Lassman, Michael E.,Li, Cai,Wu, Margaret S.,Zhang, Bei B.,Chapman, Kevin T.,Mills, Sander G.,Berger, Joel P.,Pasternak, Alexander
scheme or table, p. 6088 - 6092 (2010/11/18)
A new series of thiazole-substituted 1,1,1,3,3,3-hexafluoro-2-propanols were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Key analogs caused dose-dependent decreases in food intake and body weight in obese mice. Acute treatment with these compounds also led to a drop in elevated blood glucose in a murine model of type II diabetes.
